Direct-To-Consumer Genetic Testing Kits Vary in Predictions of Disease Risk
By Medical Xpress,
Medical Xpress
| 07. 17. 2013
An in-depth analysis and comparison study conducted by investigators at Emory's Rollins School of Public Health demonstrated variations in predicted disease risks by companies that offer direct-to-consumer personal genome testing.
Led by Cecile Janssens, PhD, research professor of Epidemiology, the team investigated DNA test results from three "direct- to-consumer" genome testing companies (23andMe, deCODEme, and Navigenics) to assess and compare their predictive abilities. Results show that predicted risks differed among the companies and were contradictory for certain traits in certain individuals.
The complete findings are available in the online edition of Genetics in Medicine.
"Although two of the companies that we studied are no longer operating, genotyping and sequencing is becoming less expensive and testing such as this is increasingly popular," explains Janssens. "The methods used for predicting these types of results are of important concern."
Test results provided by the three companies indicated an individual's risks for a large number of diseases. The study was conducted by creating DNA data for a hypothetical population of 100,000 individuals which is a less expensive and equally valid method for demonstrating the...
Related Articles
By Nahlah Ayed, CBC Listen | 10.22.2025
Egg freezing is one of today’s fastest-growing reproductive technologies. It's seen as a kind of 'fertility insurance' for the future, but that doesn’t address today’s deeper feelings of uncertainty around parenthood, heterosexual relationships, and the reproductive path forward. In this...
By [cites CGS' Katie Hasson], KCBS Radio | 11.19.2025
This is Ask An Expert, where every weekday at 9:20am, KCBS Radio is giving you direct access to top experts in various fields. Today: Gene-editing technology allows scientists to work with DNA in unprecedented ways, but there are larger scientific...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...
By Emily Mullin, Wired | 10.30.2025
In 2018, Chinese scientist He Jiankui shocked the world when he revealed that he had created the first gene-edited babies. Using Crispr, he tweaked the genes of three human embryos in an attempt to make them immune to HIV and...
